🟠 The AZALEA-TIMI 71 Study demonstrated that abelacimab, a Factor XI inhibitor, significantly reduced bleeding by 62%–69% compared to rivaroxaban in atrial fibrillation patients. 
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA